Incyte's Oral JAK Inhibitor Shows Durable Efficacy, Safety At One Year In Skin Disorder

 

• Incyte Corporation (NASDAQ: INCY) announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).

• The study previously met its primary endpoint, demonstrating that at Week 16 – patients receiving povorcitinib once daily (QD) had significantly greater decreases from baseline in Abscess and Inflammatory Nodule (AN) count versus placebo.

• Results at Week 52, which include the 36-week open-label extension period during which all patients received povorcitinib 75 mg QD, show that average efficacy was sustained for all treatment arms following the switch to povorcitinib 75 mg QD.

• Povorcitinib also demonstrated durable efficacy at Week 52 in high-threshold outcomes, as evidenced by 22-29% of patients achieving HS Clinical Response 100 (HiSCR100).

https://finance.yahoo.com/news/incytes-oral-jak-inhibitor-shows-143756238.html